Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Positive Phase 1 MRT-8102 results in GFORCE-1, targeting NLRP3-driven inflammatory conditions.
Monte Rosa Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive Phase 1 MRT-8102 results in GFORCE-1, targeting NLRP3-driven inflammatory conditions
- Key pathogenic ASCVD drivers reportedly normalized in subjects with elevated cardiovascular risk
- MRT-8102 is a NEK7-directed molecular glue degrader, supporting development beyond a single indication
- Press release and webcast presentation furnished as Exhibits 99.1 and 99.2 for detailed data and safety review
Item 8.01 · Other Events
- Phase 1 GFORCE-1 enrolled 108 obese subjects, with MRT-8102 achieving 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
- Atherosclerosis and systemic inflammation biomarkers substantially reduced, supporting MRT-8102’s potential across NLRP3/IL-1-driven diseases
- Lipoprotein(a) declined 24%, comparable to PCSK9 inhibitors, without LDL-C or triglyceride increases
- Eight-week safety profile favorable, with no serious adverse events and TEAEs of 33% versus 30% for placebo
- Phase 2 expansion planned across coronary artery disease, gout, and hidradenitis suppurativa beginning Q4 2026 through H1 2027
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 GFORCE-1 enrolled 108 obese subjects; MRT-8102 achieved 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
- ASCVD-related biomarkers declined materially, including calprotectin 56%, S100A12 46%, SAA 51%, and fibrinogen 28%
- Systemic inflammation improved, with IL-6 down 54%, hsCRP down 85%, and lipoprotein(a) down 24% without increased LDL-C or triglycerides
- Safety profile remained favorable: no serious adverse events, comparable treatment-emergent adverse events versus placebo, and no increased infection risk
- Clinical development expands across indications, with GEMINI-1 planned Q4 2026 or Q1 2027 and GFORCE-2 and GALAXY-1 planned H1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monte Rosa Therapeutics, Inc. 8-K filings
Get the next GLUE 8-K as it lands
Follow GLUE for push alerts, or ask the research agent what this filing means.